SML Genetree strengthens presence in the Middle East as a diagnostic solution provider across Dubai, Saudi Arabia, and beyond
Korea’s leading IVD company SML Genetree is further solidifying its position in the Middle Eastern healthcare market. SML Genetree announced that it has been selected as the final winner in a public tender issued by the Public Health Department under Kuwait’s Ministry of Health for the supply of respiratory pathogen diagnostic kits, marking the company’s full-scale expansion across the Middle East region.
Through this contract, SML Genetree will supply its self-developed ‘NamuPlex Respiratory Pathogen kit’ to Kuwait’s Ministry of Health. This product had already been awarded in a university hospital tender in Türkiye in 2022. In the UAE, the company has achieved rapid growth, recording an average annual sales increase of about 44% between 2023 and 2025, establishing a strong foothold in the market.
In Saudi Arabia, SML Genetree has completed SFDA (Saudi Food and Drug Authority) registration and anticipates significant sales expansion. The company emphasized that this entry into Kuwait represents more than just a new contract.
Having steadily supplied respiratory and infectious disease diagnostic products to major Middle Eastern markets—including Dubai (UAE), Saudi Arabia, and Türkiye—SML Genetree has built a strong reputation for reliability. Its recent success in Kuwait extends this track record, effectively filling the market gap created by the withdrawal of existing major suppliers, and positioning the company as a trusted diagnostic solution provider across the Middle East.
The company’s continued achievements in a region known for strict health regulations and demanding certification procedures further demonstrate that SML Genetree’s technology and global operational capabilities have reached international standards.
SML Genetree stated that being awarded the Kuwait Ministry of Health tender reflects both the proven competitiveness of its products in Türkiye and the UAE and the recognized potential for broader expansion into major Middle Eastern countries, including Saudi Arabia. The company expects continued supply and the launch of new projects across the Middle East, including Kuwait, in the near future.
Source: Medical News (의학신문)
http://www.bosa.co.kr/news/articleView.html?idxno=2260674
SML Genetree strengthens presence in the Middle East as a diagnostic solution provider across Dubai, Saudi Arabia, and beyond
Korea’s leading IVD company SML Genetree is further solidifying its position in the Middle Eastern healthcare market. SML Genetree announced that it has been selected as the final winner in a public tender issued by the Public Health Department under Kuwait’s Ministry of Health for the supply of respiratory pathogen diagnostic kits, marking the company’s full-scale expansion across the Middle East region.
Through this contract, SML Genetree will supply its self-developed ‘NamuPlex Respiratory Pathogen kit’ to Kuwait’s Ministry of Health. This product had already been awarded in a university hospital tender in Türkiye in 2022. In the UAE, the company has achieved rapid growth, recording an average annual sales increase of about 44% between 2023 and 2025, establishing a strong foothold in the market.
In Saudi Arabia, SML Genetree has completed SFDA (Saudi Food and Drug Authority) registration and anticipates significant sales expansion. The company emphasized that this entry into Kuwait represents more than just a new contract.
Having steadily supplied respiratory and infectious disease diagnostic products to major Middle Eastern markets—including Dubai (UAE), Saudi Arabia, and Türkiye—SML Genetree has built a strong reputation for reliability. Its recent success in Kuwait extends this track record, effectively filling the market gap created by the withdrawal of existing major suppliers, and positioning the company as a trusted diagnostic solution provider across the Middle East.
The company’s continued achievements in a region known for strict health regulations and demanding certification procedures further demonstrate that SML Genetree’s technology and global operational capabilities have reached international standards.
SML Genetree stated that being awarded the Kuwait Ministry of Health tender reflects both the proven competitiveness of its products in Türkiye and the UAE and the recognized potential for broader expansion into major Middle Eastern countries, including Saudi Arabia. The company expects continued supply and the launch of new projects across the Middle East, including Kuwait, in the near future.
Source: Medical News (의학신문)
http://www.bosa.co.kr/news/articleView.html?idxno=2260674